NARRATIVE REVIEW · very low certainty
Dexamethasone intravitreal implant (Ozurdex) monotherapy for uveitic macular edema secondary to non-infectious uveitis: a single-center retrospective cohort study
In uveitic macular edema secondary to non-infectious uveitis, Ozurdex monotherapy was associated with central retinal thickness reduction; signal is preliminary and not yet practice-changing.
318MDcentral retinal thickness at 12 months vs baselineLow-certainty estimate
Design Narrative-reviewn 21Funding Not reported
- Why it matters
- First single-center retrospective report of Ozurdex monotherapy outcomes in non-infectious uveitic macular edema over 12 months.
- Limitations
- Single-center retrospective cohort, small sample (n=21), no comparator arm.
Statistics · confidence intervals & p-values
central retinal thickness at 12 months vs baseline: MD 318 p<0.05
Source
Simaku E et al.. Dexamethasone intravitreal implant (Ozurdex) monotherapy for uveitic macular edema secondary to non-infectious uveitis: a single-center retrospective cohort study. International ophthalmology. Thursday, August 27, 2026.
doi:10.1007/s10792-026-04245-xRead original ↗
doi:10.1007/s10792-026-04245-xRead original ↗
Generated, then checked against the source · how this brief was built →
Sign in to rate and bookmark articles
Automated evidence summary, checked against the source. Not medical advice. Verify with the original publication.